Rubicon has successfully identified, negotiated and closed M&A deals in the Asia region. We have participated in Congressional hearings in Washington DC on China’s pursuit of a life science sector, and the implications to western business. We frequently are called on by media to comment on healthcare reforms in China and Southeast Asia.
We broker deals between firms looking to China for capital partners, regardless of whether they want to build a footprint in China today or are simply evaluating alternatives to capital sources in the west. W
e evaluate potential partners and provide an additional safeguard to companies eager to take advantage of the region’s growing healthcare consumption by knowing the right questions to ask, when, and where to go to get the best answers.